Validation of hepcidin quantification in plasma using LC-HRMS and discovery of a new hepcidin isoform

Bioanalysis

Volumn 5, Issue 20, 2013, Pages 2509-2520

  Rochat, Bertrand ^a   Peduzzi, Davide ^a   McMullen, Justin ^a   Favre, Amélie ^a   Kottelat, Emmanuel ^a   Favrat, Bernard ^a   Tissot, Jean Daniel ^b   Angelillo Scherrer, Anne ^c   Bromirski, MacIej ^d   Waldvogel, Sophie ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Service Regional Vaudois de Transfusion Sanguine   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Thermo Fischer Scientific   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; EDETIC ACID; HEPARIN; HEPCIDIN;

ACCURACY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; EXTRACTION; FEMALE; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PRECIPITATION; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SWINE; VALIDATION PROCESS;

AMINO ACID SEQUENCE; CALIBRATION; CHROMATOGRAPHY, LIQUID; FEMALE; HEPCIDINS; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE MICROEXTRACTION;

EID: 84886507551     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.225     Document Type: Article

References (37)

1. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim. Biophys. Acta 1823(9), 1434-1443 (2012).
2. Vermeulen E, Vermeersch P. Hepcidin as a biomarker for the diagnosis of iron metabolism disorders: a review. Acta Clin. Belg. 67(3), 190-197 (2012).
3. Troutt JS, Rudling M, Persson L et al. Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clin. Chem. 58(8), 1225-1232 (2012).
4. Campostrini N, Traglia M, Martinelli N et al. Serum levels of the hepcidin-20 isoform in a large general population: the Val Borbera study. J. Proteomics 76, 28-35 (2012).
5. Ho S, Pothoulakis C, Koon H W. Antimicrobial peptides and colitis. Curr. Pharm. Des. 19(1), 40-47 (2013).
6. Kroot JJ, van Herwaarden AE, Tjalsma H et al. Second round robin for plasma hepcidin methods: frst steps toward harmonization. Am. J. Hematol. 87(10), 977-983 (2012).
7. Swinkels DW, Girelli D, Laarakkers C et al. Advances in quantitative hepcidin measurements by time-of-fight mass spectrometry. PLoS ONE 3(7), e2706 (2008).
8. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin. Chem. 56(10), 1570-1579 (2010).
9. Anderson DS, Kirchner M, Kellogg M et al. Design and validation of a high-throughput matrix-assisted laser desorption ionization time-of-fight mass spectrometry method for quantifcation of hepcidin in human plasma. Anal. Chem. 83(21), 8357-8362 (2011).
10. Tomosugi N, Kawabata H, Wakatabe R et al. Detection of serum hepcidin in renal failure and infammation by using ProteinChip System. Blood 108(4), 1381-1387 (2006).
11. Li H, Rose MJ, Tran L et al. Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J. Pharmacol. Toxicol. Methods 59(3), 171-180 (2009).
12. Itkonen O, Parkkinen J, Stenman UH, Hämäläinen E. Preanalytical factors and reference intervals for serum hepcidin LC-MS/MS method. Clin. Chim. Acta 413(7-8), 696-701 (2012).
13. Bansal SS, Abbate V, Bomford A et al. Quantitation of hepcidin in serum using ultra-high-pressure liquid chromatography and a linear ion trap mass spectrometer. Rapid Commun. Mass Spectrom. 24(9), 1251-1259 (2010).
14. Hwang SI, Lee Y Y, Park JO et al. Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method. Clin. Chim. Acta 412(23-24), 2241-2247 (2011).
15. Murphy AT, Witcher DR, Luan P, Wroblewski VJ. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 110 (3), 1048-1054 (2007).
16. Wolff F, Deleers M, Melot C, Gulbis B, Cotton F. Hepcidin-25: measurement by LC-MS/MS in serum and urine, reference ranges and urinary fractional excretion. Clin. Chim. Acta 423, 99-104 (2013).
17. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 112(10), 4292-4297 (2008).
18. Busbridge M, Griffths C, Ashby D et al. Development of a novel immunoassay for the iron regulatory peptide hepcidin. Br. J. Biomed. Sci. 66 (3), 150-157 (2009).
19. Koliaraki V, Marinou M, Vassilakopoulos TP et al. A novel immunological assay for hepcidin quantifcation in human serum. PLoS ONE 4(2), e4581 (2009).
20. Butterfeld AM, Luan P, Witcher DR et al. A dual-monoclonal sandwich ELISA specifc for hepcidin-25. Clin. Chem. 56 (11), 1725-1732 (2010).
21. Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J. Proteomics 73(3), 527-536 (2010).
22. Ramanathan R, Jemal M, Ramagiri S et al. It is time for a paradigm shift in drug discovery bioana lysis: from SRM to HRMS. J. Mass Spectrom. 46(6), 595-601 (2011).
23. Rochat B. Quantitative/qualitative ana lysis using LC-HRMS: the fundamental step forward for clinical laboratories and clinical practice. Bioanalysis 4(14), 1709-1711 (2012).
24. Rochat B, Favre A and Sottas PE. Metabotype ana lysis for personalized biology: a new bioanalytical territory for high-resolution MS. Bioanalysis 5 (10), 1149-1152 (2013).
25. Ramagiri S, Garofolo F. Large molecule bioana lysis using Q-TOF without predigestion and its data processing challenges. Bioanalysis 4(5), 529-540 (2012).
26. Henry H, Sobhi HR, Scheibner O, Bromirski M, Nimkar SB, Rochat B. Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun. Mass Spectrom. 26(5), 499-509 (2012)
27. Rochat B, Kottelat E, McMullen J. The future key role of LC-high-resolution-MS analyses in clinical laboratories: a focus on quantifcation. Bioanalysis 4(24), 2939-2958 (2012)
28. Kaufmann A, Butcher P, Maden K, Walker S, Widmer M. Quantitative and confrmative performance of liquid chromatography coupled to high-resolution mass spectrometry compared with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 25(7), 979-992 (2011).
29. Itkonen O, Stenman UH, Parkkinen J et al. Binding of hepcidin to plasma proteins. Clin. Chem. 58(7), 1158-1160 (2012).
30. Heinig K, Wirz T. Determination of taspoglutide in human and animal plasma using liquid chromatography-tandem mass spectrometry with orthogonal column-switching. Anal. Chem. 81(10), 3705-3713 (2009).
31. Shah VP, Midha KK, Findlay JW et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17(12), 1551-1557 (2000).
32. Waldvogel S, Pedrazzini B, Vaucher P et al. Clinical evaluation of iron treatment effciency among non-anemic but iron-defcient female blood donors: a randomized controlled trial. BMC Med. 10, 8 (2012).
33. Halquist MS, Sakagami M, Karnes HT. Determination of oxyntomodulin, an anorectic polypeptide, in rat plasma using 2D-LC-MS/MS coupled with ion pair chromatography. J. Chromatogr. B 903, 102-111 (2012).
34. Kaufmann A, Widmer M, Maden K. Post-interface signal suppression, a phenomenon observed in a single-stage Orbitrap mass spectrometer coupled to an electrospray interfaced liquid chromatograph. Rapid Commun. Mass Spectrom. 24(14), 2162-2170 (2010).
35. Kaufmann A, Walker S. Accuracy of relative isotopic abundance and mass measurements in a single-stage orbitrap mass spectrometer. Rapid Commun. Mass Spectrom. 26(9), 1081-1090 (2012).
36. Baart AM, van Noord PA, Vergouwe Y et al. High prevalence of subclinical iron defciency in whole blood donors not deferred for low hemoglobin. Transfusion 1537-2995 (2012).
37. Moe MK, Hardand JM, Tor-Arne H. Novel circulating isoforms of hepcidin. Clin. Chem. doi: 10.1373/clinchem.2013.208371 (2013) (Epub ahead of print).